Robitaille P, Marie P J, Delvin E E, Lortie L, Glorieux F H
Acta Paediatr Scand. 1984 May;73(3):315-24. doi: 10.1111/j.1651-2227.1994.tb17741.x.
Eleven uremic children with osteodystrophy aged 3 to 17 years were studied during administration of 1,25-(OH)2D3 for periods up to 21 months. Nine children presented with pure hyperparathyroidism, one with osteomalacia and one with mixed bone disease. Bone biopsies were performed before initiation of therapy and after 6 to 21 months of treatment following double tetracycline labeling. Skeletal lesions were improved but not cured in 5 of 9 children with hyperparathyroidism. In three instances lesions remained unchanged and worsened in one. No significant change was observed in the child with osteomalacia. Moderate improvement was noted in the patient with mixed bone disease. The propensity to develop hypercalcemia was the major factor associated with treatment failure since it precluded administration of adequate amounts of medication. Therapy with 1,25-(OH)2D3 was associated with a spectacular improvement in growth velocity in two of six children under age twelve.
对11名年龄在3至17岁患有骨营养不良的尿毒症儿童进行了研究，研究期间给予1,25 - (OH)₂D₃长达21个月。9名儿童表现为单纯性甲状旁腺功能亢进，1名患有骨软化症，1名患有混合性骨病。在治疗开始前以及双四环素标记后治疗6至21个月后进行了骨活检。9名甲状旁腺功能亢进儿童中有5名的骨骼病变有所改善但未治愈。有3例病变无变化，1例病变恶化。骨软化症患儿未观察到明显变化。混合性骨病患者有中度改善。发生高钙血症的倾向是与治疗失败相关的主要因素，因为它妨碍了给予足够剂量的药物。在6名12岁以下儿童中，有2名使用1,25 - (OH)₂D₃治疗后生长速度显著提高。
